Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382238700> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4382238700 endingPage "31" @default.
- W4382238700 startingPage "26" @default.
- W4382238700 abstract "Original patented drugs and generic drugs using the same pharmaceutical ingredients may have different clinical efficacies and prices. This study was designed to compare the clinical efficacy and cost-effectiveness of original imported temozolomide capsules and those generic capsules manufactured domestically, with a pharmacoeconomic evaluation being performed. In this retrospective study, 103 glioma patients from 2008 to 2018 were divided into the generic temozolomide group (72 cases) and the imported temozolomide group (31 cases). The 2-year overall survival (OS) and disease progression free survival (PFS) of the two groups were analyzed using Kaplan Meier survival curves, and the 2-year disease control rate and 2-year survival rate were calculated. The incidence of adverse reactions was also compared between the two groups. A pharmacoeconomic evaluation was performed on the two groups according to the total cost of treatment per capita. The 2-year disease control rate of the domestic drug group was 52.8% and the imported drug group was 67.7%. The 2-year survival rate of the domestic drug group was 68.10%, with the imported drug group being 74.20%. The total cost of treatment per patient/2-year PFS time in the domestic drug group was 7000.55 yuan/month; while the imported drug group was 7705.41 yuan/month. The total cost of treatment per patient/2-year OS time in domestic drug group was 5821.20 yuan/month, while the imported drug group was 7035.53 yuan/month. There was no significant difference between the domestic drug group and the imported drug group in treatment efficacy and the total cost/2-year PFS time of the two groups were not significantly different. However, the total cost/2-year OS time of the domestic group was significant lower than the imported group, revealing a certain cost-effective advantage." @default.
- W4382238700 created "2023-06-28" @default.
- W4382238700 creator A5005901099 @default.
- W4382238700 creator A5014911630 @default.
- W4382238700 creator A5018822768 @default.
- W4382238700 creator A5038347628 @default.
- W4382238700 creator A5044083641 @default.
- W4382238700 creator A5047434331 @default.
- W4382238700 creator A5054284198 @default.
- W4382238700 creator A5073819805 @default.
- W4382238700 creator A5087554605 @default.
- W4382238700 creator A5088526794 @default.
- W4382238700 date "2023-06-01" @default.
- W4382238700 modified "2023-10-06" @default.
- W4382238700 title "Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma" @default.
- W4382238700 cites W2074139195 @default.
- W4382238700 cites W2082302274 @default.
- W4382238700 cites W2084451812 @default.
- W4382238700 cites W2096287682 @default.
- W4382238700 cites W2123748842 @default.
- W4382238700 cites W2164061282 @default.
- W4382238700 cites W2290568182 @default.
- W4382238700 cites W2592264367 @default.
- W4382238700 doi "https://doi.org/10.1016/j.ipha.2023.04.006" @default.
- W4382238700 hasPublicationYear "2023" @default.
- W4382238700 type Work @default.
- W4382238700 citedByCount "0" @default.
- W4382238700 crossrefType "journal-article" @default.
- W4382238700 hasAuthorship W4382238700A5005901099 @default.
- W4382238700 hasAuthorship W4382238700A5014911630 @default.
- W4382238700 hasAuthorship W4382238700A5018822768 @default.
- W4382238700 hasAuthorship W4382238700A5038347628 @default.
- W4382238700 hasAuthorship W4382238700A5044083641 @default.
- W4382238700 hasAuthorship W4382238700A5047434331 @default.
- W4382238700 hasAuthorship W4382238700A5054284198 @default.
- W4382238700 hasAuthorship W4382238700A5073819805 @default.
- W4382238700 hasAuthorship W4382238700A5087554605 @default.
- W4382238700 hasAuthorship W4382238700A5088526794 @default.
- W4382238700 hasBestOaLocation W43822387001 @default.
- W4382238700 hasConcept C120665830 @default.
- W4382238700 hasConcept C121332964 @default.
- W4382238700 hasConcept C126322002 @default.
- W4382238700 hasConcept C141071460 @default.
- W4382238700 hasConcept C2776694085 @default.
- W4382238700 hasConcept C2777389519 @default.
- W4382238700 hasConcept C2780035454 @default.
- W4382238700 hasConcept C2781072439 @default.
- W4382238700 hasConcept C61511704 @default.
- W4382238700 hasConcept C71924100 @default.
- W4382238700 hasConcept C98274493 @default.
- W4382238700 hasConceptScore W4382238700C120665830 @default.
- W4382238700 hasConceptScore W4382238700C121332964 @default.
- W4382238700 hasConceptScore W4382238700C126322002 @default.
- W4382238700 hasConceptScore W4382238700C141071460 @default.
- W4382238700 hasConceptScore W4382238700C2776694085 @default.
- W4382238700 hasConceptScore W4382238700C2777389519 @default.
- W4382238700 hasConceptScore W4382238700C2780035454 @default.
- W4382238700 hasConceptScore W4382238700C2781072439 @default.
- W4382238700 hasConceptScore W4382238700C61511704 @default.
- W4382238700 hasConceptScore W4382238700C71924100 @default.
- W4382238700 hasConceptScore W4382238700C98274493 @default.
- W4382238700 hasIssue "1" @default.
- W4382238700 hasLocation W43822387001 @default.
- W4382238700 hasOpenAccess W4382238700 @default.
- W4382238700 hasPrimaryLocation W43822387001 @default.
- W4382238700 hasRelatedWork W2002120878 @default.
- W4382238700 hasRelatedWork W2003938723 @default.
- W4382238700 hasRelatedWork W2047967234 @default.
- W4382238700 hasRelatedWork W2118496982 @default.
- W4382238700 hasRelatedWork W2275480158 @default.
- W4382238700 hasRelatedWork W2364998975 @default.
- W4382238700 hasRelatedWork W2439875401 @default.
- W4382238700 hasRelatedWork W4238867864 @default.
- W4382238700 hasRelatedWork W2519357708 @default.
- W4382238700 hasRelatedWork W2525756941 @default.
- W4382238700 hasVolume "1" @default.
- W4382238700 isParatext "false" @default.
- W4382238700 isRetracted "false" @default.
- W4382238700 workType "article" @default.